Alumni
This person is a member of Sanger Institute Alumni.
Hristina’s work focused on identifying therapeutic vulnerabilities in cancer through the studies of complex biological models such as organoids. She conducted high-throughput drug sensitivity screening of large cohorts of cell lines and organoids in collaboration with Mosaic Therapeutics to inform the development of targeted drug combinations for patients with limited treatment options.
She also played a key role in the single-cell RNA-seq project aimed at building a cancer plasticity atlas, where, as part of a team, she implemented, optimised, and automated steps of the organoid pipeline critical for the dataset generation and collaboration with Parse Biosciences and Helmholtz Munich.
During her time in the Garnett lab, Hristina contributed to the WRN project with GSK, supporting the discovery of novel Werner helicase inhibitors to selectively target microsatellite unstable cancers, and conducted synthetic lethal CRISPR-Cas9 screens to prioritise therapeutic targets in other projects. She represented the Wellcome Sanger Institute at the Herschel Programme for Women in Technical Leadership.
Hristina’s work reflects a strong commitment to translating cancer genomics research into improved patient outcomes.